Sangamo Therapeutics (NASDAQ:SGMO) Stock Price Expected to Rise, HC Wainwright Analyst Says

Sangamo Therapeutics (NASDAQ:SGMO) had its price objective increased by HC Wainwright from $5.00 to $10.00 in a research note published on Tuesday morning, Benzinga reports. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock.

Separately, StockNews.com assumed coverage on shares of Sangamo Therapeutics in a research report on Sunday, July 28th. They set a “sell” rating for the company. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $4.33.

Sangamo Therapeutics Price Performance

Shares of SGMO stock opened at $2.16 on Tuesday. The firm has a 50-day moving average of $1.02 and a 200-day moving average of $0.74. Sangamo Therapeutics has a one year low of $0.29 and a one year high of $2.30. The company has a market cap of $449.76 million, a P/E ratio of -1.57 and a beta of 1.10.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.01). The business had revenue of $0.36 million for the quarter, compared to analysts’ expectations of $11.40 million. Sangamo Therapeutics had a negative net margin of 2,033.69% and a negative return on equity of 273.25%. As a group, research analysts expect that Sangamo Therapeutics will post -0.47 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sangamo Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Acadian Asset Management LLC increased its stake in shares of Sangamo Therapeutics by 4.0% in the first quarter. Acadian Asset Management LLC now owns 4,943,260 shares of the biopharmaceutical company’s stock worth $3,311,000 after purchasing an additional 192,385 shares in the last quarter. Renaissance Technologies LLC grew its stake in Sangamo Therapeutics by 58.8% in the 2nd quarter. Renaissance Technologies LLC now owns 4,126,577 shares of the biopharmaceutical company’s stock valued at $1,479,000 after buying an additional 1,528,600 shares in the last quarter. Marshall Wace LLP grew its stake in Sangamo Therapeutics by 56.3% in the 2nd quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company’s stock valued at $207,000 after buying an additional 207,476 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Sangamo Therapeutics during the first quarter worth $331,000. Finally, Vontobel Holding Ltd. boosted its holdings in shares of Sangamo Therapeutics by 412.3% in the third quarter. Vontobel Holding Ltd. now owns 300,000 shares of the biopharmaceutical company’s stock worth $259,000 after acquiring an additional 241,440 shares during the period. 56.93% of the stock is currently owned by institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.